Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485920 | 1.00 | MAOB (0.52) | MAOBCAPN1PARP1MAOAXDH | |
| SCHEMBL29435848 | 0.79 | BACE1 (0.47) | MAOBCAPN1PARP1MAOAMEN1 | |
| SCHEMBL5997891 | 0.78 | MAOB (0.52) | MAOBCAPN1PARP1MAOAXDH | |
| SCHEMBL14523845 | 0.78 | MAOB (0.52) | MAOBCAPN1PARP1MAOAXDH | |
| SCHEMBL29589724 | 0.78 | MAOB (0.52) | MAOBCAPN1PARP1MAOAXDH | |
| SCHEMBL23965858 | 0.75 | TYR (0.53) | CAPN1ABCG2CTSLALDH1A1 | |
| SCHEMBL10824463 | 0.70 | TUBB1 (0.76) | MAOBCAPN1PARP1MAOAXDH | |
| SCHEMBL10824465 | 0.70 | TUBB1 (0.76) | MAOBCAPN1PARP1MAOAXDH | |
| SCHEMBL2027068 | 0.70 | MAOB (1.00) | MAOBCAPN1PARP1MAOAXDH | |
| SCHEMBL799750 | 0.70 | MAOB (1.00) | MAOBCAPN1PARP1MAOAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | claimed |
| EP-1623704-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-08 | — | — | EP | claimed |
| US-7498357-B2 | 1-[2,3-dihydro-4-hydroxy-2-(1-hydroxy-1,5-dimethyl-4-hexenyl)-benzofuran-5-yl]-3-(4-hydroxyphenyl)-2-propen-1-one; antiinflammatory, anticarcinogenic agent; nitrogen monoxide (NO) production suppresant, aldose reductase inhibitor; chronic rheumatic arthritis, osteoarthritis, gouty arthritis | TAKARA BIO INC. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-7498357-B2 | 1-[2,3-dihydro-4-hydroxy-2-(1-hydroxy-1,5-dimethyl-4-hexenyl)-benzofuran-5-yl]-3-(4-hydroxyphenyl)-2-propen-1-one; antiinflammatory, anticarcinogenic agent; nitrogen monoxide (NO) production suppresant, aldose reductase inhibitor; chronic rheumatic arthritis, osteoarthritis, gouty arthritis | TAKARA BIO INC. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20070112066-A1 | Remedy | TAKARA BIO INC. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112066-A1 | Remedy | TAKARA BIO INC. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1702912-A1 | REMEDY | TAKARA BIO INC. (JP) | 2006-09-20 | — | — | EP | disclosed |
| EP-1623704-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112066-A1 | Remedy | AKR1B1, AKR1C2, ALDOA | MAOB 679/4885CAPN1 4528/4885PARP1 4726/4885 |
| US-20070092551-A1 | Therapeutic agent | FABP4, GPR119, IAPP | MAOB 4382/4885CAPN1 2082/4885PARP1 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.